9901494-6

IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 39/395 — A1

(11) International Publication Number: **WO 98/16249**

(43) International Publication Date: 23 April 1998 (23.04.98)

(21) International Application Number: PCT/US97/18035

(22) International Filing Date: 3 October 1997 (03.10.97)

(30) Priority Data:
60/028,270 — 11 October 1996 (11.10.96) — US

(71) Applicant: BRISTOL–MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Princeton, NJ 08543–4000 (US).

(72) Inventors: ARUFFO, Alejandro, A.; 33 Cheston Court, Belle Mead, NJ 08502 (US). CHALUPNY, N., Jan; 5603 Phinney Avenue North, Seattle, WA 98103 (US). CHEN, Lieping; 8045 40th Avenue N.E., Seattle, WA 98115 (US). MITTLER, Robert, S.; 6 Jenny Jump Court, Flemington, NJ 08822 (US). SHUFORD, Walter, W.; 21700 N.E. 62nd, Redmond, WA 98053 (US). SIADAK, Anthony, W.; 6210 1st Avenue N.W., Seattle, WA 98107 (US).

(74) Agents: SORRENTINO, Joseph, M. et al.; Bristol–Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543–4000 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: METHODS AND COMPOSITIONS FOR IMMUNOMODULATION

(57) Abstract

The instant invention discloses the unexpected result that two anti–4–1BB monoclonal antibodies can inhibit both primary and secondary humoral responses to at least T–cell dependent antigens *in vivo*. Such antibodies provide a novel approach to immunosuppression and cancer therapy *in vivo*.